AmacaThera

AmacaThera is a clinical-stage biotechnology company revolutionizing drug delivery with its proprietary AmacaGel™ platform, enabling localized, sustained therapeutic release. Founded on the research of biomaterials expert Dr. Molly Shoichet, the company is advancing innovative solutions in post-surgical pain management and oncology, including AMT-143, a non-opioid anesthetic showing promising Phase 1 trial results. With a collaborative, science-driven culture, AmacaThera seeks passionate professionals eager to challenge conventional therapeutics and drive meaningful advancements in patient health. Joining AmacaThera means contributing to cutting-edge innovations that have the potential to transform medicine.